BioCentury
ARTICLE | Clinical News

RP101: Interim Phase I data

August 21, 2006 7:00 AM UTC

Interim data from an open-label Phase I trial in 22 patients showed that RP101 plus gemcitabine led to survival rates of 68% and 39% at 6 and 12 months, respectively. The estimated median survival was...